Legal & General Group Plc Trims Position in IQVIA Holdings Inc. (NYSE:IQV)

Legal & General Group Plc decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 22.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,158,581 shares of the medical research company's stock after selling 335,298 shares during the period. Legal & General Group Plc owned approximately 0.64% of IQVIA worth $227,673,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Synergy Asset Management LLC bought a new position in IQVIA during the fourth quarter valued at approximately $33,000. Lee Danner & Bass Inc. bought a new stake in IQVIA in the fourth quarter worth $44,000. Zions Bancorporation N.A. boosted its position in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares during the period. Versant Capital Management Inc grew its stake in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after buying an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in shares of IQVIA in the fourth quarter worth about $60,000. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Down 1.1 %

IQV stock traded down $1.62 during trading on Tuesday, hitting $149.30. 307,656 shares of the stock traded hands, compared to its average volume of 1,384,224. The firm's 50 day moving average is $181.23 and its two-hundred day moving average is $198.80. The stock has a market cap of $26.32 billion, a price-to-earnings ratio of 19.91, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent research reports. Royal Bank of Canada restated an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Barclays reiterated an "equal weight" rating and set a $170.00 price target (down from $235.00) on shares of IQVIA in a report on Thursday, April 10th. Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Truist Financial lowered their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. Finally, Morgan Stanley raised their target price on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Six research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $241.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.